New push to stop HIV in black women: testing Real-World delivery of prevention shots
NCT ID NCT05514509
Summary
This study tested different ways for clinics to offer a long-acting injection (called cabotegravir or Apretude) to prevent HIV. It involved 370 Black cisgender and transgender women without HIV, as well as clinic staff. The main goal was to see which clinic strategies worked best to make this prevention method easy to access, acceptable, and practical for patients and healthcare providers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Washington D.C., District of Columbia, 20005, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20010, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20017, United States
-
GSK Investigational Site
Miami, Florida, 33137, United States
-
GSK Investigational Site
Orlando, Florida, 32808, United States
-
GSK Investigational Site
Tampa, Florida, 33611, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33401, United States
-
GSK Investigational Site
Atlanta, Georgia, 30303, United States
-
GSK Investigational Site
Atlanta, Georgia, 30309, United States
-
GSK Investigational Site
Atlanta, Georgia, 30312, United States
-
GSK Investigational Site
Bridgeport, Kansas, 06605, United States
-
GSK Investigational Site
Detroit, Michigan, 48201, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89104, United States
-
GSK Investigational Site
Brooklyn, New York, 10001, United States
-
GSK Investigational Site
New York, New York, 10029, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19114, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19147, United States
-
GSK Investigational Site
Memphis, Tennessee, 38104, United States
-
GSK Investigational Site
Dallas, Texas, 75201, United States
-
GSK Investigational Site
Houston, Texas, 77006, United States
-
GSK Investigational Site
Houston, Texas, 77021, United States
-
GSK Investigational Site
Norfolk, Virginia, 23510, United States
Conditions
Explore the condition pages connected to this study.